Benito Munoz

62 year

Health Technology

Consumer Services

Profile

Benito Munoz worked as a Director in Research Laboratories at Merck & Co., Inc. from 1999 to 2008.
He then worked as a Director in Medicinal Chemistry at The Broad Institute, Inc. from 2009 to 2013.
After that, he worked as a Director at Karyopharm Therapeutics, Inc. and as an Executive Vice President in Drug Discovery at Proteostasis Therapeutics, Inc. from 2016 to 2017.
Munoz holds a graduate degree from Brock University and a doctorate degree from the University of Toronto.

Former positions of Benito Munoz

Companies	Position	End
The Broad Institute, Inc. The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	2013-10-31
MERCK & CO., INC.	Corporate Officer/Principal	2008-09-30
KARYOPHARM THERAPEUTICS INC.	Director/Board Member	-
PROTEOSTASIS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	-

See the detail of Benito Munoz's experience

Training of Benito Munoz

Brock University	Graduate Degree
University of Toronto	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Benito Munoz's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
MERCK & CO., INC.	Health Technology
KARYOPHARM THERAPEUTICS INC.	Health Technology

Private companies	2
Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.	Health Technology
The Broad Institute, Inc. The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA.	Health Technology